Carcinoma hepatocelular

Por el personal de Mayo Clinic
07 de octubre de 2026

Investigación

Los médicos y científicos de Mayo Clinic estudian maneras nuevas de mejorar el diagnóstico y el tratamiento del carcinoma hepatocelular.

Mayo Clinic es reconocido como un centro de Programas Especializados de Excelencia en Investigación (SPORE, por sus siglas en inglés) por la investigación del cáncer hepatobiliar, con el financiamiento del Instituto Nacional del Cáncer de Estados Unidos. El programa SPORE de cáncer hepatobiliar se dedica a mejorar el diagnóstico y tratamiento del cáncer de hígado y de los conductos biliares.

Publicaciones

Consulte una lista de publicaciones escritas por los médicos de Mayo Clinic sobre el carcinoma hepatocelular en PubMed, un servicio de la National Library of Medicine (Biblioteca Nacional de Medicina).

  1. Elsevier Point of Care. Clinical Overview: Hepatocellular carcinoma. https://www.clinicalkey.com. Accessed Nov. 18, 2024.
  2. Hepatocellular carcinoma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514. Accessed July 25, 2025.
  3. Primary liver cancer treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq. Accessed Nov. 18, 2024.
  4. Liver (hepatocellular) cancer prevention (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq. Accessed Nov. 18, 2024.
  5. Schwartz JM, et al. Clinical features and diagnosis of hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed July 30, 2025.
  6. Abdalla EK, et al. Overview of treatment approaches for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 5, 2025.
  7. Stuart KE. Systemic treatment for advanced hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024.
  8. Schwartz JM, et al. Epidemiology and risk factors for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024.
  9. Curley SA, et al. Surgical resection of hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024.
  10. Tsoulfas G, et al. Liver transplantation for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 5, 2025.
  11. Palliative care. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1454. Accessed Nov. 18, 2024.
  12. Hepatitis C prevention and control. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis-c/prevention/index.html. Accessed Nov. 18, 2024.
  13. 2020-2025 Dietary Guidelines for Americans. U.S. Department of Health and Human Services and U.S. Department of Agriculture. https://www.dietaryguidelines.gov. Accessed Nov. 18, 2024.
  14. TACE. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/chemoembol. Accessed Nov. 18, 2024.
  15. Radioembolization (Y90). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/radioembol. Accessed Nov. 18, 2024.
  16. Thermal ablation for tumor treatment. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/thermal-ablation-therapy. Accessed Nov. 18, 2024.
  17. Liver cancer. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/liver-cancer/about/index.html. Accessed Nov. 18, 2024.
  18. Hepatitis B vaccine. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis-b/vaccination/index.html. Accessed Feb. 7, 2025.
  19. Feldman M, et al., eds. Hepatic tumors and cysts. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 11th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed July 25, 2025.
  20. DeVita VT Jr, et al., eds. Cancer of the liver. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. ProQuest Ebook Central. Wolters Kluwer; 2023. Accessed Feb. 11, 2025.
  21. Suriawinata A. Pathology of malignant liver tumors. https://www.uptodate.com/contents/search. Accessed July 25, 2025.
  22. Kalman RS, et al. Epidemiology, clinical manifestations, diagnosis and treatment of fibrolamellar carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 6, 2025.
  23. Ferri FF. Jaundice in the adult patient. In: Ferri's Clinical Advisor 2026. Elsevier; 2026. https://www.clinicalkey.com. Accessed Aug. 1, 2025.
  24. McPherson RA, et al., eds. Evaluation of liver function. In: Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 1, 2025.
  25. Reig M, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology. 2022; doi:10.1016/j.jhep.2021.11.018.
  26. Cancer stat facts: Liver and intrahepatic bile duct cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/livibd.html. Accessed Aug. 5, 2025.
  27. Tecentriq (prescribing information). Genentech; 2024. https://www.tecentriq.com. Accessed Aug. 5, 2025.
  28. Lenvima (prescribing information). Eisai; 2025. https://www.lenvima.com. Accessed Aug. 5, 2025.
  29. Health Education & Content Services. Liver cancer: Hepatocellular carcinoma. Mayo Clinic; 2023.
  30. Nimmagadda R. Allscripts EPSi. Mayo Clinic. Feb. 26, 2025.
  31. Liver SPOREs. National Cancer Institute. https://dctd.cancer.gov/research/spores/focus-area/liver. Accessed Aug. 6, 2025.
  32. Santol J, et al. An APRI+ALBI-based multivariable model as preoperative predictor for posthepatectomy liver failure. Annals of Surgery. 2023; doi:10.1097/SLA.0000000000006127.
  33. Starlinger P, et al. Combined APRI/ALBI score to predict mortality after hepatic resection. BJS Open. 2021; doi:10.1093/bjsopen/zraa043.
  34. Kern AE, et al. MicroRNA based prediction of posthepatectomy liver failure and mortality outperforms established markers of preoperative risk assessment. Annals of Surgical Oncology. 2025; doi:10.1245/s10434-025-17528-x.
  35. Dong Y, et al. Preoperative von Willebrand factor is an independent predictive biomarker for posthepatectomy liver failure — A multivariable model with APRI+ALBI. Liver Transplantation. 2025; doi:10.1097/LVT.0000000000000676.